Phase II open label study of CT-2106 as a single agent in patients with advanced metastatic ovarian cancer who have failed one prior platinum and taxane based regimen
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2014
At a glance
- Drugs CT 2106 (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors CTI BioPharma
- 14 Jan 2008 Status changed from in progress to completed.
- 21 Aug 2006 Status change
- 18 Nov 2005 New trial record.